Skip to main content

Stem cells slashed alcoholism rates in rats. Can it do the same for humans?

Stem cells are undifferentiated cells with the ability to transform, as required, into many different types of cell in the body. They have previously been responsible for a number of major medical breakthroughs, doing everything from restoring sensation to people with paralysis to enabling almost blind people to read again. Now a new study from researchers at the University of Chile has another application for them: Helping fight alcoholism.

In clinical trials, the researchers found that one dose of human mesenchymal stem cells injected intravenously into rats significantly reduced the amount of alcohol they would willingly imbibe. Within 48 hours of treatment, the rats — which were previously downing the size-adjusted equivalent of a bottle of vodka per day — reduced their alcohol intake by up to 90 percent. The effects of one dose lasted up to five weeks.

“Alcohol use disorders constitute a leading cause of morbidity and premature mortality worldwide,” Dr. Fernando Ezquer, one of the researchers on the project, told Digital Trends. “Several studies in humans and rodents have shown that chronic alcohol consumption leads to an increase in inflammatory cytokines, both in the periphery and the brain, and this alcohol-induced neuroinflammation remains up-regulated for long periods even after discontinuation of alcohol consumption. This phenomenon perpetuates alcohol consumption and is also associated with a marked increase in the risk of relapse in abstinent patients. Drugs currently available for alcoholics patients have very low effectiveness and are not focused in reducing neuroinflammation.”

Cell therapy based on mesenchymal stem cells is increasingly emerging as a clinical option for diseases in which this type of neuroinflammation occurs. Ezquer said that, in the case of this study, the stem cells work as a combination of an anti-inflammatory and antioxidant medication which could greatly reduce alcohol intake.

“We have proved efficacy and safety using rats [selectively] bred as alcohol consumers,” Ezquer continued. “This is a very robust animal model of alcoholism since these rats consume the equivalent in humans of over one bottle of vodka every day. We believe that in humans presenting an alcohol use disorder, this type of cell therapy may reasonably be used in conjunction with a cognitive-behavioral intervention. For other diseases, over 1,200 patients have received this type of cells.”

The researchers are currently harvesting small nano-particles which are shed by mesenchymal stem cells. These could then be administered as an intranasal spray. The team is also on the lookout for clinical partners interested in transferring these studies to humans.

A paper describing the work was recently published in the journal Scientific Reports.

Editors' Recommendations

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
This AI cloned my voice using just three minutes of audio
acapela group voice cloning ad

There's a scene in Mission Impossible 3 that you might recall. In it, our hero Ethan Hunt (Tom Cruise) tackles the movie's villain, holds him at gunpoint, and forces him to read a bizarre series of sentences aloud.

"The pleasure of Busby's company is what I most enjoy," he reluctantly reads. "He put a tack on Miss Yancy's chair, and she called him a horrible boy. At the end of the month, he was flinging two kittens across the width of the room ..."

Read more
Digital Trends’ Top Tech of CES 2023 Awards
Best of CES 2023 Awards Our Top Tech from the Show Feature

Let there be no doubt: CES isn’t just alive in 2023; it’s thriving. Take one glance at the taxi gridlock outside the Las Vegas Convention Center and it’s evident that two quiet COVID years didn’t kill the world’s desire for an overcrowded in-person tech extravaganza -- they just built up a ravenous demand.

From VR to AI, eVTOLs and QD-OLED, the acronyms were flying and fresh technologies populated every corner of the show floor, and even the parking lot. So naturally, we poked, prodded, and tried on everything we could. They weren’t all revolutionary. But they didn’t have to be. We’ve watched enough waves of “game-changing” technologies that never quite arrive to know that sometimes it’s the little tweaks that really count.

Read more
Digital Trends’ Tech For Change CES 2023 Awards
Digital Trends CES 2023 Tech For Change Award Winners Feature

CES is more than just a neon-drenched show-and-tell session for the world’s biggest tech manufacturers. More and more, it’s also a place where companies showcase innovations that could truly make the world a better place — and at CES 2023, this type of tech was on full display. We saw everything from accessibility-minded PS5 controllers to pedal-powered smart desks. But of all the amazing innovations on display this year, these three impressed us the most:

Samsung's Relumino Mode
Across the globe, roughly 300 million people suffer from moderate to severe vision loss, and generally speaking, most TVs don’t take that into account. So in an effort to make television more accessible and enjoyable for those millions of people suffering from impaired vision, Samsung is adding a new picture mode to many of its new TVs.
[CES 2023] Relumino Mode: Innovation for every need | Samsung
Relumino Mode, as it’s called, works by adding a bunch of different visual filters to the picture simultaneously. Outlines of people and objects on screen are highlighted, the contrast and brightness of the overall picture are cranked up, and extra sharpness is applied to everything. The resulting video would likely look strange to people with normal vision, but for folks with low vision, it should look clearer and closer to "normal" than it otherwise would.
Excitingly, since Relumino Mode is ultimately just a clever software trick, this technology could theoretically be pushed out via a software update and installed on millions of existing Samsung TVs -- not just new and recently purchased ones.

Read more